{"id":"NCT00376675","sponsor":"Alliance for Clinical Trials in Oncology","briefTitle":"Methylphenidate in Treating Patients With Fatigue Caused by Cancer","officialTitle":"Long Acting Methylphenidate (Concertaâ„¢) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2010-06","completion":"2010-06","firstPosted":"2006-09-15","resultsPosted":"2014-10-10","lastUpdate":"2016-08-01"},"enrollment":148,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Fatigue","Unspecified Adult Solid Tumor, Protocol Specific"],"interventions":[{"type":"DRUG","name":"methylphenidate hydrochloride","otherNames":[]},{"type":"OTHER","name":"placebo","otherNames":[]}],"arms":[{"label":"Arm I","type":"EXPERIMENTAL"},{"label":"Arm II","type":"PLACEBO_COMPARATOR"}],"summary":"RATIONALE: Methylphenidate may help relieve fatigue caused by cancer. It is not yet known whether methylphenidate is more effective than a placebo in relieving fatigue and improving quality of life in patients with cancer.\n\nPURPOSE: This randomized phase III trial is studying methylphenidate to see how well it works in treating patients with fatigue caused by cancer.","primaryOutcome":{"measure":"Prorated AUC of Total Fatigue as Measured by the Brief Fatigue Inventory (BFI) at Baseline and at Weeks 1-4","timeFrame":"Baseline to week 4","effectByArm":[{"arm":"Methylphenidate","deltaMin":50.33,"sd":20.32},{"arm":"Placebo","deltaMin":47.15,"sd":17}],"pValues":[{"comp":"OG000 vs OG001","p":"0.317"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":238,"countries":["United States"]},"refs":{"pmids":["20625123"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":68},"commonTop":["Insomnia","Headache","Anxiety","Dizziness","Abdominal pain"]}}